Sarah Gitto, PhD

Radiology
Call 800-789-7366
Penn Medicine Provider

About me

  • Instructor A of Pathology and Laboratory Medicine
  • Research Assistant Professor of Radiology

Spoken languages

English
English

Insurance accepted

Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.

Locations

Qualifications and experience

Treatments and conditions

Research

Publications

Koopman LA, Alemdehy F, dr Poot SAH, Paauwe M, Wang W, Epstein K, van den Brink E, Gorlani A, Verzijl D, Brandhorst M, Franken P, Vries LS, Gielen E, Plantinga TS, Houtkamp M, Engelberts PJ, Egerog FL, Thalhauser CJ, Bosgra S, Gitto SB, Powell DJ Jr, Gamse JT, Overdijk MB, Breiji ECW Preclinical comparison of two CD3xB7H4 bispecific antibodies for solid tumor therapy reveals CD3 affinity-dependent potency and tolerability tradeoffs , Molecular Cancer Therapeutics : 2026

Gitto SB, Hughes S, Paul M, Bom S, Burchett R, Morreale BG, Pannucci A, Rono C, Weigel C, Wolf CL, Williams JE Jr, Cohn W, Gibson H, Dolatshahi S, Gupta A, Rutkowshi MR, Anderson KG Opportunities to enhance cancer research through advocate-researcher partnerships , Cancer Research: 2026

Gitto SB, Riad A, McArthur A, Babazada H, Nakkina S, Simpkins F, Mankoff DA, Mach RH, Farwell MD PARP-targeted theranostic approach to image and treat ovarain cancer , Jounral of Nuclear Medicine, 67: 2026,262154-262154

Kinose Y, Xu H, Kim H, Wang X, Kumar S, Shan X, George E, Medvedev S, Ortiz A, Gitto SB. Whicker M, D’Andrea K, Wubbenhost B, Hallberg D, O’Connor M, Schwartz L, Hwang W, Nathanson KL, Mills G, Velculescu VE, Wang T, Brown E, Drapkin R, Simpkins F Target clear cell ovarian cancers with ARID1A loss by combination inhibition of BRD4 and ATR , Molecular Cancer Therapeutics: 2025

Onecha VV, Gitto SB, Riad A, Farwell MD, Pryma DA, Bertolet A A monte carlo dosimetry-based cell survival model incorporating spatial and temporal heterogeneity for RPT preclinical studies: TU-730-209-2 , Medical Physics, 52: 2025,e70059479

Nakkina SP, Medvedev S, Ma K, Anderson M, Simpkins F, Powell DJ Jr., Gitto SB VEGF inhibition enhances immune checkpoint blockade efficacy in ovarian cancer. , Proceedings of the AACR Special Conference in Cancer Research: Advances in Ovarian Cancer Research: 2025

Riad A, McAuthur A, Babazada H, Mankoff D, Mach RH, Farwell FD, Gitto SB Preclinical evaluation of PTT, an At-211-labeled rucaparib analogue, as a therapeutic agent for cancer therapy , Proceedings of the AACR Special Conference in Cancer Research: Advances in Ovarian Cancer Research: 2025

Gitto SB, Riad A, McArthur A, Simpkins F, Pryma DA, Farwell MD PARP-targeted alpha therapy for the treatment of PARP-inhibitor resistant ovarian cancer , Proceedings of the AACR Special Conference in Cancer Research: Advances in Ovarian Cancer Research: 2025

Babazada H, Martorano P, Lee H, Geng S, Batra V, Maris JM, Pryma DA, Gitto SB, Farwell MD. PARP1-targeted alpha therapy enhances target expression , European Journal of Nuclear Medicine and Molecular Imaging, 15(1): 2025,63

Onecha VV, Suarez-Garcia D, Bosque JJ, Lee H, Simpkins F, Gitto SB, Pryma DA, Bertolet A. Space- and time-defined Monte Carlo dosimetry explains ovarian cancer cell viability in targeted a-particle therapy with astatine 211-ParaThanatrace. , International Journal of Radiation Oncology, Biology, and Physics: 2025

View all publications